BioCentury | Jul 14, 2014
Company News

Santaris, Servier, miRagen deal

The partners extended by two years to October 2016 a 2011 deal to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen’s preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195 , plus an undisclosed...
BioCentury | Apr 24, 2014
Targets & Mechanisms

Mired in miR-25

Preclinical data showing that microRNA-25 inhibition can help treat heart failure directly contradict a 2013 paper suggesting that decreased levels of the miRNA provoke the condition. 1,2 Although the new study shows that blocking microRNA-25...
BioCentury | Jun 3, 2013
Company News

miRagen, Santaris, Servier deal

Servier exercised its right to add a third target to a 2011 deal with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. Servier's target selection triggered the first undisclosed milestone payment to miRagen....
BioCentury | May 3, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Publication and contact information Endocrine/metabolic disease Metabolic syndrome; obesity MicroRNA-208a (miR-208a) Studies in mice suggest antagonizing miR-208a...
...metabolic syndrome and obesity. In a mouse model of diet-induced obesity, an oligonucleotide antagonist of miR-208a...
...weight gain compared with an untargeted oligonucleotide control. Next steps include preclinical development of the miR-208a...
BioCentury | May 3, 2012
Cover Story

Heart beats fat

...antimiR. Olson's team suspected that the effects of knocking down miR-208a stemmed from a key miR-208a-regulated...
...Med13 compared with normal miR-208a expression. "Because MED13 was one of the strongest targets of miR-208a...
...MED13 . Because miR-208a and miR-208b are so similar, it is possible that knocking down miR-208a...
BioCentury | Nov 7, 2011
Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
BioCentury | Oct 24, 2011
Company News

miRagen, Santaris, Servier deal

Servier partnered with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195, as well as a cardiovascular microRNA modulator yet to be identified....
BioCentury | Oct 19, 2011
Top Story

Servier, miRagen in cardiovascular deal

Servier (Neuilly-sur-Seine, France) partnered with miRagen Therapeutics Inc. (Boulder, Colo.) to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 (miR-208) and miR-15/195, as well as a cardiovascular...
BioCentury | Sep 12, 2011
Clinical News

miRagen preclinical data

In a rat model of heart failure, subcutaneous antimiR-208 significantly improved survival vs. both a control oligonucleotide and placebo at 8 weeks post-induction of stress (80% vs. 20% for both controls, p<0.004 for both). The...
BioCentury | Nov 11, 2010
Targets & Mechanisms

Change of heart on miR-21

A team led by researchers at The University of Texas Southwestern Medical Center at Dallas and miRagen Therapeutics Inc. has reported that blocking microRNA-21 has no effect on stress-induced cardiac dysfunction. The findings prompted miRagen...
Items per page:
1 - 10 of 12